Insider sale activity at Taysha Gene Therapies (NASDAQ: TSHA)

Rhea-AI Filing Summary

Taysha Gene Therapies reporting person submitted a Form 144 relating to Common Stock sales tied to an RSU award that vested and was settled in stock on 02/27/2026, where consideration was the reporting person’s continued service.

The filing lists prior sales during the past three months: 23,533 shares on 01/23/2026 for $111,781.75, 7,107 shares on 01/26/2026 for $32,763.27, and 697 shares on 02/04/2026 for $3,150.44.

Insights

Corporate Governance Analyst

Form 144 notifies planned resale of vested RSU shares and lists recent insider dispositions.

The filing states an RSU award vested and was settled in stock on 02/27/2026; the reporting person received shares in exchange for continued service. The notice signals intent to sell rather than an acquisition.

Recent reported dispositions total 31,337 shares across three dated transactions in 01/2026 and 02/2026. Cash proceeds for those sales are listed in the filing.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Maxim Group LLC 300 Park Avenue, 16th Floor New York NY 10022	2405	10990.85	273915373	02/27/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/27/2026	RSU Award	Issuer			2405	02/27/2026	Vested grant settled in stock; consideration was Reporting Person's continued service as an employee of the Issuer.

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Rumana Haque-Ahmed c/o Taysha Gene Therapies, Inc. 3000 Pegasus Park Drive, Suite 1430 Dallas TX 75247	Common Stock	01/23/2026	23533	111781.75
Rumana Haque-Ahmed c/o Taysha Gene Therapies, Inc. 3000 Pegasus Park Drive, Suite 1430 Dallas TX 75247	Common Stock	01/26/2026	7107	32763.27
Rumana Haque-Ahmed c/o Taysha Gene Therapies, Inc. 3000 Pegasus Park Drive, Suite 1430 Dallas MA 75247	Common Stock	02/04/2026	697	3150.44

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the TSHA Form 144 disclose about the RSU settlement?

The filing states an RSU award vested and was settled in stock on 02/27/2026. It says the consideration for the grant was the reporting person’s continued service as an employee, per the filing.

How many TSHA shares were sold by the reporting person in the past three months?

The filing lists three recent dispositions totaling 31,337 shares: 23,533 on 01/23/2026, 7,107 on 01/26/2026, and 697 on 02/04/2026, with proceeds shown for each sale.

What proceeds did the reporting person receive from the recent TSHA sales?

The filing shows proceeds of $111,781.75 for 01/23/2026, $32,763.27 for 01/26/2026, and $3,150.44 for 02/04/2026, as reported in the Form 144.

Does the Form 144 state whether the issuer receives proceeds from these sales?

The Form 144 indicates the sales arise from an RSU settlement to the reporting person and prior open-market dispositions; the filing does not state that the issuer receives proceeds from these resales.

Who is the reporting person named on the TSHA Form 144?

The filing identifies Rumana Haque-Ahmed c/o Taysha Gene Therapies at the address provided. The notice lists her as the reporting person associated with the RSU settlement and recent sales.